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Background: Despite much work, safe and effective approaches to attack and deplete the long-lived reservoir of
cells latently infected with HIV-1 remain an elusive goal. Patients infected with HIV-1 treated with cytotoxic agents
or bone marrow transplantation can experience decreases in the reservoir of HIV-1 latently infected cells. Other
viruses capable of long-term latency, such as herpesviruses, can sense host cell apoptosis and respond by initiating
replication. These observations suggest that other viruses capable of long-term latency, like HIV-1, might also sense
when its host cell is about to undergo apoptosis and respond by initiating replication.
Results: Pro-monocytic (U1) and lymphoid (ACH-2) HIV-1 persistently infected cell lines were treated with cytotoxic
drugs – doxorubicin, etoposide, fludarabine phosphate, or vincristine – and activation of latent HIV-1 was evaluated
using assays for HIV-1 RNA and p24 production. Both cell lines showed dose-dependent increases in apoptosis and
associated HIV-1 activation following exposure to the cytotoxic agents. Pretreatment of the cells with the pan-caspase
inhibitor Z-VAD-FMK prior to exposure to the cytotoxic agents inhibited apoptosis and viral activation. Direct exposure
of the latently infected cell lines to activated caspases also induced viral replication. HIV-1 virions produced in
association with host cell apoptosis were infectious.
Conclusions: The results indicate that latent HIV-1 can sense when its host cell is undergoing apoptosis and responds
by completing its replication cycle. The results may help explain why patients treated with cytotoxic regimens for bone
marrow transplantation showed reductions in the reservoir of latently infected cells. The results also suggest that the
mechanisms that HIV-1 uses to sense and respond to host cell apoptosis signals may represent helpful new targets for
approaches to attack and deplete the long-lived reservoir of cells latently infected with HIV-1.
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Effective antiretroviral therapy (ART) can reduce HIV-1
circulating in peripheral blood to below the limits of de-
tection. However, ART cannot completely eradicate
HIV-1 because of the persistent reservoir of latently in-
fected cells [1–4], and reviewed in [5–7]. Much work
has recently focused on finding ways to deplete or elim-
inate the long-lived reservoir of latently infected cells.
One approach that has gained attention is termed “shock
(or kick) and kill,” which aims to deplete the reservoir
by activating latent HIV while using ART to prevent* Correspondence: Zeichner@gwu.edu
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(http://creativecommons.org/publicdomain/zeinfection of new cells (reviewed in [8–11]). However, it
has been challenging to develop safe and effective agents
that can activate HIV-1 in all latently infected cells. Agents
that have been studied include those acting through the
NF-κB pathway [12–16] and agents that activate HIV-1 by
altering the epigenetic environment of the integrated pro-
virus. Epigenetic agents that have been studied as HIV ac-
tivators include DNA methylation inhibitors [17–19],
histone deacetylase inhibitors (HDACis) [20–24],
disulfiram [25] and vorinostat [26–28]. Although such
agents can activate HIV-1 in vivo, they fail to completely
purge latent reservoirs from the infected individuals [29].
Some reports suggest that HDACis are less able to activate
HIV in a primary cell latency model [30] or in resting CD4
+ T cells from ART-treated HIV-1-infected patients [31]
compared to infected transformed cell lines. Other efforts
have gone into developing less toxic latency reversingcle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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signaling and NF-κB pathways, such as prostratin [15, 32,
33] and bryostatin-1 [29, 34]. However, there are still im-
portant concerns with these compounds because PKC sig-
naling has widespread effects on host cell metabolism, so
agents that target PKC signaling may raise regulatory con-
cerns (reviewed in [35, 36]).
While several approaches aimed at activating latent
HIV-1 have been developed, none of them have proven
effective at activating all latent viruses. We previously
studied the ability of different activating agents to induce
HIV-1 replication in several distinct cell line models of
latent infection, which may reflect some of the diversity
that exists among latently infected cells in vivo, and
found that agents that activate HIV-1 in some of the cell
lines could not activate the virus in other cells lines and
that some agents showed antagonistic effects in some
model cell lines [37].
Recent work showed that the reservoir of cells latently
infected with HIV-1 may be even more difficult to attack
than was previously appreciated. For example, a study
showed that T-cell activation does not induce all of the
functional latent provirus present, and a significant pro-
portion of these non-induced proviruses are replication-
competent [38]. If agents are unable to activate all latent
HIV-1 in the reservoir, much of the provirus that re-
mains may be capable of reinitiating and sustaining in-
fection. In the “shock and kill” approach essentially all
HIV-1 in the latent reservoir must be eradicated to effect
a cure.
While agents specifically designed to activate HIV-1
have proven to be incompletely effective, other thera-
peutic interventions, involving cytotoxic chemotherapy
and bone marrow transplantation (BMT), appear to have
been relatively more effective at attacking and depleting
the HIV-1 latent reservoir. These examples include the
only patient known to have been cured of HIV-1 infec-
tion, and other patients that while not cured neverthe-
less experienced substantial reductions in the reservoir
[39–42], although for these patients rebound viremia
was observed 15 weeks after treatment interruption [43].
In these studies, in which patients were treated with
bone marrow transplantation with continued antiretro-
viral therapy or using a donor who had the Δ32CCR5
mutation, it is understandable why no new cells were in-
fected, but it is not clear how and why BMT or associ-
ated cytotoxic conditioning regimen eliminated or
significantly reduced HIV-1 latent reservoirs in these pa-
tients. One possible, but unlikely explanation is that the
cytotoxic agents simply killed all the latently infected
cells. Another possible explanation for the reservoir re-
ductions seen in the bone marrow transplantation pa-
tients is that the latently infected cells were eliminated
by a phenomenon analogous to the well-known graft vs.tumor effect that significantly contributes to the cancer
cures observed after bone marrow transplantation [44,
45]. However, HIV-1 patients treated with bone marrow
transplantation for lymphoma showed only a weak anti-
HIV-1 cellular immune response [43]. The precise
mechanisms responsible for the HIV reservoir reduc-
tions seen in association with bone marrow transplant-
ation remain unclear.
HIV-1, like many other viruses, has evolved ways to
inhibit host cell apoptosis [46–51], an important way for
the virus to enhance its replication when host cells initi-
ate the apoptotic program as a way of limiting replica-
tion within the host. When herpesviruses fail to prevent
the host cell from undergoing apoptosis, they apparently
have another strategy to try to ensure production of
some progeny virions. We recently found that when
KSHV [52], HHV6A, HHV6B, HHV7 and EBV [53] de-
tect that the host cell is undergoing apoptosis, they
adopt an emergency escape mechanism, an Alternative
Replication Program (ARP), a process that leads to the
rapid production of large amounts of virus with de-
creased infectivity. Caspase-3 is necessary and sufficient
to initiate the ARP. The Roizman lab showed that herpes
simplex virus type 1 (HSV-1) has a similar alternative
replication program when it senses that its host cell is
about to undergo apoptosis [54, 55]. The existence of an
apoptosis-triggered ARP makes evolutionary sense.
Without an apoptosis-triggered ARP, once the apoptotic
program begins, the host cell would die before any pro-
geny virus was produced. An apoptosis-triggered ARP
would therefore appear to be a helpful survival strategy
for any virus capable of long-term latency. Although her-
pesviruses and retroviruses are members of completely
different Families, any virus capable of long term latent
infection should still be subject to the same evolutionary
pressures. An analogous apoptosis-triggered replication
program could help provide an explanation for the re-
ductions in latent HIV-1 reservoirs observed in patients
treated with cytotoxic agents during bone marrow trans-
plantation. Apoptotic signals sensed by the virus would
then trigger viral replication, leading to a reduction in
the viral latent reservoir, when the patients are also
treated with antiviral agents or transplanted with cells
incapable of being infected with HIV-1, in a process be-
yond those attributed to other mechanisms.
To explore the hypothesis that HIV-1 can sense and
respond to host cell apoptosis, we tested the ability of
HIV-1 latently infected cell lines to initiate viral replica-
tion in response to cytotoxic agents, and directly to
activated-caspases. We found that apoptosis triggered by
cytotoxic drugs triggered HIV-1 replication, and that
inhibiting apoptosis with caspase inhibitors led to a re-
duction in viral replication. The process produced infec-
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Fig. 1 Cytotoxic drugs induce apoptosis and HIV-1 replication in U1 cells. The cells were treated with (a) etoposide (0–25 μM), (b) doxorubicin
(0–10 μM), (c) vincristine (0–5 μM) and (d) fludarabine phosphate (0–10 μM). At 36 h post treatment, apoptosis was assessed by Annexin V
staining (solid line) and HIV-1 activation was determined by qRT-PCR for unspliced viral RNA (dashed line) and ELISA for HIV-1 p24 viral
antigen (dotted line) in culture supernatant. (e) PMA (25 ng/ml) was used as a positive control, bar graph shows apoptosis (%, white bars) and
fold increase in HIV-1 unspliced RNA production (black bars). (f) HIV-1 production after PMA treatment was determined by ELISA for p24
antigen in culture supernatant from PMA treated U1 cells. The data represented are the mean ± standard deviation (n = 3)
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Fig. 2 Induction of HIV-1 replication by apoptosis in ACH-2 cells. 36 h post treatment with (a) etoposide (0–5 μM), (b) doxorubicin (0–10 μM), (c)
vincristine (0–10 nM) and (d) fludarabine phosphate (0–10 μM), apoptosis was assessed by Annexin-V staining (solid line). HIV-1 activation was
measured as fold change (compared to control DMSO treated cells) in accumulation of unspliced HIV-1 RNA by qRT-PCR (dashed line). HIV-1
production after drug exposure was determined using ELISA for HIV-1 p24 (dotted line). (e) For a positive control, cells were treated with TNF-α
(20 ng/ml) and HIV-1 activation was measured by qRT-PCR as mentioned above. (f) Virus production from ACH-2 treated with TNF-α was
determined by ELISA for HIV-1 p24 antigen. The data represented are the mean ± standard deviation (n = 3)
Khan et al. Retrovirology  (2015) 12:42 Page 4 of 19
Khan et al. Retrovirology  (2015) 12:42 Page 5 of 19observed following activation with conventional agents,
and occurred in latently infected cells arrested in G1, in
addition to actively replicating cells. The presence of ac-
tivated caspases was directly associated with the initi-
ation of viral replication, suggesting that HIV-1 can
sense host cell apoptosis and respond by initiating
replication.
Results
Apoptosis triggers HIV-1 activation in latently-infected
cells
To examine the effects of cytotoxic drug-induced apop-
tosis on latent HIV-1, we studied pro-monocytic U1 cells
latently infected with HIV-1. U1 cells contain two inte-
grated copies of the viral genome and, under unstimu-
lated conditions, express low levels of viral transcripts
encoding Tat, Rev, and Nef, but little or no full-length
viral RNA [56, 57]. Cells were treated with four pro-
apoptotic cytotoxic agents frequently used for cancer
chemotherapy and in bone marrow transplant condition-
ing regimens: etoposide (Fig. 1a), doxorubicin (Fig. 1b),
vincristine (Fig. 1c), and fludarabine phosphate (Fig. 1d).
In addition to the cytotoxic agents, aliquots of cells were
also incubated with DMSO (at a concentration equal to
the one the cells were exposed to after addition of the
cytotoxic agents) as negative control and treated with
PMA (25 ng/ml) as a positive control for viral induction
through a PKC-related pathway (Fig. 1e and f). Cells
were collected 36 h post treatment and apoptosis was
evaluated by flow cytometry for Annexin-V+/7-AAD
staining. HIV-1 activation was monitored by p24-
capture ELISA and qRT-PCR for unspliced HIV-1 RNA.
Exposure to each of the four cytotoxic agents caused
dose-dependent increases in apoptosis, with concurrent
production of viral RNA within the cells and p24 in cul-
ture supernatant (Fig. 1 a–d). Fig. 1 show that with in-
creasing concentration of each drug, the number of
Annexin-V+ cells significantly increased with simultan-
eous production of viral RNA and p24 production. Fig. 1
e and f show that treatment of the cells with PMA,
which activates HIV-1 through the classical NF-κB path-
way, activates HIV-1 in these cells, and that DMSO, the
solvent in which we dissolved the cytotoxic agents did
not activate HIV-1. Some of the cytotoxic agents, etopo-
side and doxorubicin, produced larger fold-activation
levels than the PMA positive control inducer, while
others were less effective (vincristine and fludarabine
phosphate), but all were highly activating, with the least
potent activator, fludarabine phosphate, producing a
~10-fold increase in HIV RNA.
To confirm that apoptosis activates latent HIV-1 in
other cell types, we studied a lymphocytoid HIV-1 la-
tently infected cell line, ACH-2, [58]. HIV-1 in ACH-2
cells has a defect in the Tat responsive element (TAR)due to a single point mutation in the loop of the TAR
hairpin [59]. ACH-2 cells were treated with the cytotoxic
drugs and harvested 36 h post treatment. The cells were
also incubated with TNF-α (20 ng/ml) and DMSO to
serve as positive and negative controls (Fig. 2e and f). We
found a similar dose-dependent pattern of apoptosis-
mediated HIV-1 activation as observed in U1 cells (Fig. 1),
when ACH-2 cells were treated with cytotoxic agents;
etoposide (Fig. 2a), doxorubicin (Fig. 2b), vincristine
(Fig. 2c), and fludarabine phosphate (Fig. 2d). The in-
crease in apoptosis was associated with HIV-1 activation
at the RNA and protein levels and was observed for all
cytotoxic drugs. ACH-2 cells were more sensitive to eto-
poside and vincristine-mediated cell death (Fig. 2a and c)
compared to U1 cells (Fig. 1a and c). It is interesting to
note that apoptosis induced by different drugs produced
different levels of HIV-1 activation. While a detailed ex-
planation of the mechanisms underlying these differences
must await future work, the different cytotoxic agents in-
duce apoptosis through different mechanisms, induce
apoptosis at different concentrations, and the latently in-
fected cells have different sensitivity to apoptotic agents
[60, 61]. In spite of observed difference in the apoptosis
dose-response in the different cells, apoptosis was consist-
ently associated with HIV-1 activation. Taken together,
these results suggest that apoptosis broadly triggers HIV-1
replication in both HIV-1 latently infected cell line model
systems. When we reanalyzed the data, examining HIV ac-
tivation as a function of apoptosis, we found a clear correl-
ation, with large increases in HIV-1 activation observed
when between 30 and 50 % of cells were apoptotic, de-
pending on the cytotoxic agent and cell line. We found
that there was a significant association (Spearman’s coeffi-
cient (ρ) ranged from 0.88 to 0.99) for all pro-apoptotic
chemotherapy agents used to treat U1 (Fig. 3) and ACH-2
cells (Fig. 4).
These data indicate that cytotoxic drug induced-
apoptosis can reactivate latent HIV-1 in ACH-2 and U1
cells. It is possible that apoptosis may also affect active
HIV-1 replication. To examine this, we infected Jurkat T-
cells with HIV-1, and then treated the cells with cytotoxic
drugs. We observed no significant increase in HIV-1 RNA
in the cells treated with apoptosis inducers compared with
infected cells that were not treated with apoptotic agents
(Fig. 5). Rather, we observed significant reductions in the
HIV RNA produced by the cells treated with the cytotoxic
agents. The data suggest that while treatment with agents
that induce apoptosis can trigger activation of latent HIV,
treatment with agents that induce apoptosis during active
HIV replication does not enhance viral replication, and if
anything works against effective viral replication, an obser-
vation consistent with the observations that HIV-1 has sev-
eral mechanisms aimed at preventing host cell apoptosis
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Fig. 3 HIV-1 activation in response to apoptosis induction in U1 cells. The figure shows the relationship between HIV-1 replication and apoptosis
triggered by cytotoxic drugs: (a) etoposide, (b) doxorubicin, (c) vincristine and (d) fludarabine phosphate. Apoptosis and HIV-1 activation was
assessed as mentioned in Fig. 1 and Fig. 2. Spearman correlation coefficient (ρ) for apoptosis vs. HIV-1 activation for all the drugs was≥ 0.9. Values
represented are the mean ± SD (n = 3)
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The cells from the monocyte-macrophage lineage and
resting CD4+ T cells constitute the bulk of the HIV-1 la-
tent reservoir, with resting CD4+ T cells constituting a
major part. To assess the ability of apoptosis to induce
HIV activation in quiescent or G1-arrested cells we studied
activation in synchronized U1 cells. The percentage of
cells in G1-phase was substantially increased (to ~81 %
from ~32 %) by simvastatin treatment prior to induction
of apoptosis by cytotoxic drugs (Fig. 6a). Drug-induced
apoptosis strongly activated HIV expression in the G1-
arrested cells, and showed a more pronounced increase in
HIV-1 activation compared to conventional activation by
PMA (Fig. 6b). Apoptosis can apparently strongly activate
HIV-1 in both actively dividing cells and in G1-arrested
cells.Kinetics of HIV-1 activation in response to apoptosis
induction
HIV-1 replication triggered by cytotoxic agents is tightly
linked to apoptosis (Figs. 3 and 4). To study the kinetics
of HIV activation following induction of apoptosis, we
performed a time course experiment in which we deter-
mined HIV-1 expression at serial times after treatment
with cytotoxic drugs (Fig. 7). We observed that apoptosis
(Fig. 7a and c) was significantly increased 8 h after
treatment in both the ACH-2 and U1 cells. However, the
induction of HIV-1 expression (Fig. 7b and d) was evi-
dent only after 18 h. The conventional NF-κB pathway
activated by PMA or TNF-α showed significant induc-
tion of HIV-1 expression at 8 h. This data suggests that
HIV-1 activation induced by apoptosis has slower kinet-
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Fig. 4 Relationship between apoptosis and HIV-1 activation in ACH-2 cells. The figure shows the relationship between HIV-1 replication and apoptosis
triggered by cytotoxic drugs: etoposide (a) etoposide, (b) doxorubicin, (c) vincristine and (d) fludarabine phosphate. Results are pooled from three
independent experiments and are shown as the mean ± SD of three independent experiments. The Spearman correlation coefficient (ρ) for apoptosis vs.
HIV-1 activation for all the drugs was≥ 0.86
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apoptosis-triggered HIV replication.
Apoptosis-mediated HIV-1 activation produces infectious
HIV-1 virions
It is possible that the pro-apoptotic treatments merely
led to the non-productive synthesis of HIV-1 RNA and
protein, without the production of infectious virions. To
determine whether HIV-1 activation by the cytotoxic
treatments actually produced infectious virions, we used
the reporter cell line 1G5, a Jurkat derivative containing
a stably integrated HIV-LTR-luciferase construct [62].
The IG5 cell line enables evaluation of infectious virus
because it has an HIV LTR that controls expression of a
luciferase reporter gene. When HIV infects the 1G5
cells, after reverse transcription and integration, produc-
tion of Tat by the infecting virus transactivates theluciferase reporter. We tested the infectivity of virions
released from ACH-2 cells treated with cytotoxic drugs
or TNF-α as a positive control. (After activation, U1
cells do not produce virus capable of infecting other
cells [63, 64].) We also treated the 1G5 cells infected
with virus produced by the ACH-2 cells exposed to the
cytotoxic agents with zidovudine (AZT) to confirm that
the activation of the luciferase reporter was due to HIV
replication. We added aliquots of the supernatants from
the cells exposed to the cytotoxic agents or a positive
control inducer, TNF-α, normalized for p24 content, and
assayed for luciferase activity after 48 h. We found that
the 1G5 cells showed large increases in luciferase activity
when exposed to supernatants from cells treated with
the cytotoxic agents or the positive control activator,
TNF-α (Fig. 8). The amounts of luciferase produced by



















































Fig. 5 Effect of apoptosis induction on active HIV-1 replication. Jurkat cells were infected with HIV-1. The infected cells were treated with apoptosis
inducers: doxorubicin (0.5 μM), etoposide (0.5 μM), vinicristine (1 nM) and fludarabine phosphate (1 μM). Apoptosis (grey bars) was assessed by Annexin-V
staining and HIV-1 unspliced RNA was assessed by qRT-PCR (black bars) were assessed 48 h post infection. Values presented as mean ± SD, with statistically
significant differences indicated by asterisks (**p≤ 0.001 and *p≤ 0.05 vs DMSO-treated cells)
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tion by the different agents was approximately equal and
approximately equal to the infectivity of virus produced
through the conventional pathway. AZT treatment of
the 1G5 cells completely inhibited luciferase expression,
suggesting that the observed increase in luciferase activ-
ity is due infectious virions. A minimal signal was ob-
tained in mock treated cells that were exposed to culture
supernatant from Jurkat cells treated with TNF-α (Fig. 8).
This observation suggests that infectious virions pro-
duced the large increases in luciferase activity, and that
the increases in luciferase activity were not due to re-
sidual cytotoxic drugs or TNF-α or factors released from
activated cells. Overall, the data suggests that apoptosis
activates latent HIV-1, which results in the production
of infectious virions with specific infectivities that similar
to virions produced via a conventional pathway.Activation of HIV-1 replication by cytotoxic drugs
depends on caspase activity
Caspases play an essential role in mediating the apop-
totic cascade. To determine whether caspase activity was
necessary for HIV-1 activation by cytotoxic agents and
apoptosis, we performed experiments with the general
pan-caspase inhibitor, Z-VAD-FMK. We pre-treated
U1 cells with increasing concentrations of Z-VAD-
FMK (0–100 μM) for 2 h and induced apoptosis with
etoposide (Fig. 9a), doxorubicin (Fig. 9b) and vincris-
tine (Fig. 9c). We evaluated apoptosis by Annexin-V
staining and measured viral activation by assaying for
HIV-1 RNA and p24 production. We observed thatpre-treatment with the general caspase inhibitor sig-
nificantly reduced drug-induced apoptosis and subse-
quent HIV-1 replication in a dose-dependent manner
when compared to untreated cells, suggesting a rela-
tionship between apoptosis and HIV-1 activation
(Fig. 9 a–c).
We also evaluated the association between apoptosis
and activation of HIV-1 replication in lymphocytic
cells. We pre-treated ACH-2 cells with Z-VAD-FMK
(0–200 μM) and induced apoptosis as described above
(Fig. 10). The data obtained in lymphocytic cells,
ACH-2, confirmed the results we obtained using U1
cells. Pre-treatment of the cells with Z-VAD-FMK
prior to activation by PMA or TNF-α failed to com-
pletely block HIV-1 activation, showing that canonical
NF-κB-mediated HIV-1 activation is neither apoptosis-
nor caspase activation-dependent. In contrast, Z-VAD-
FMK treatment prior to activation of ACH-2 cells by
TNF-α modestly increased production of HIV-1 RNA
and protein, presumably because the Z-VAD-FMK pro-
vided some protection against apoptosis occurring in
the cells that accompanied conventional HIV-1 replica-
tion, enabling production of additional HIV-1 RNA
and protein (Fig. 10 d–e) [65, 66]. Overall, the data
suggests that apoptosis-mediated activation of HIV-1
replication by cytotoxic drugs requires caspase activity.Caspase dependence of apoptosis-triggered HIV-1
activation
The experiments with Z-VAD-FMK (Figs. 9 and 10)







































































Fig. 6 Apoptosis-mediated HIV activation in G1-arrested cells. (a) Synchronization of U1 culture using simvastatin to enrich the cells in G1-phase.
(b) Apoptosis in synchronized cells was induced by doxorubicin (2.5 μM), etoposide (5 μM) or vincristine (5 μM). Cells induced with PMA were
used as positive control for HIV-1 activation. Apoptosis (white bars) was assessed by Annexin-V staining and HIV activation was measured by qPCR
for unspliced HIV-1 RNA
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by cytotoxic agents. We then conducted additional ex-
periments using specific caspase inhibitors to further
confirm that caspases were necessary for HIV-1 activa-
tion associated with apoptosis and to identify require-
ments for caspase-associated HIV-1 activation. We
treated U1 cells with specific caspase inhibitors alone or
in combinations (see Fig. 11 legends) before treating the
cells with etoposide (Fig. 11a) and doxorubicin (Fig. 11b).
We found that the inhibitors of caspase-3 (Z-DEVD-
FMK) and caspase-8 (Z-IETD-FMK) reduced apoptosis
and HIV-1 replication following treatment with etopo-
side and doxorubicin. We found that the caspase-9 in-
hibitor (Z-LEHD-FMK) also produced modest inhibition
of apoptosis and subsequent HIV-1 replication, but did
not inhibit activation as effectively as we observed with
the caspase-3 and -8 inhibitors. When we treated cells
with combinations of the different caspase inhibitors
prior to treating the cells with the cytotoxic agents, we
observed that the inhibition of either caspase-3 or -8reduced apoptosis and HIV-1 activation, and that the ef-
fect was greater than that observed with the caspase-9
inhibitor (Fig. 11). The data suggest that caspase-3 and
-8 are necessary for the activation of latent HIV-1 in as-
sociation with apoptosis.
Caspase-3 and -8 activities are sufficient for HIV-1
activation
Given that caspase-3 and -8 inhibition are associated
with decreases in HIV-1 activation following treatment
with cytotoxic drugs, suggesting that these caspases are
necessary for the HIV-1 activation response, we wanted
to establish whether these activated caspases would be
sufficient to initiate HIV-1 replication. We transfected
U1 cells with plasmids that express functional activated
caspase-3 (pcasp3-Wt-GFP) [67] and caspase-8 (pEGFP-
N1-Caspase-8) [68] as GFP fusion proteins, along with a
plasmid that expresses only GFP unfused to any other
protein, pmaxGFP (Lonza), as negative control. We used
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Fig. 7 Apoptosis induced HIV-1 reactivation kinetics. The time course of HIV-1 activation study was determined in ACH-2 cells (a and b) and U1
cells (c and d) after treatment with apoptosis inducing agent. The cells were harvested at the indicated time-points (0, 2, 4, 8, 18, 24, and 48 h)
and assayed for apoptosis (a and c) by Annexin-V staining and HIV-1 activation was quantitated by RT-qPCR for HIV-1 unspliced RNA (b and d).
Cells treated with PMA (for U1 cells) and TNF-α (for ACH-2) were used as positive controls
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staining and GFP expression by flow cytometry. We found
that apoptosis, as judged by Annexin-V positivity, accom-
panied GFP expression in the cells transfected with the
caspase-GFP fusion plasmids, the HIV-1 RNA produced by
these cells, and HIV-1 p24 released by the cells (Fig. 12).
These data indicate that activated caspase-3 or caspase-8 is
sufficient to activate HIV-1 from latency.
Since the apoptotic agents or active caspases might have
activated HIV-1 expression through a process indirectly re-
lated to apoptosis that is via some bystander effect, an inci-
dental triggering of viral replication in cells exposed to
signaling factors released by cells undergoing apoptosis, we
tested whether HIV-1 activation is apoptosis-specific
phenomenon. We transfected U1 cells with plasmids ex-
pressing caspase-GFP fusion proteins and used flowcytometry to determine whether expression of the HIV-1
p24 protein was produced in the GFP-expressing cells or in
all the cells generally. We found that almost all (~90 %) of
the cells expressing either caspase-3 or caspase-8 GFP fu-
sion proteins also expressed HIV-1 p24 protein (Fig. 12c,
lower panel), compared to control cells that had not been
transfected with any plasmid and cells transfected with the
control plasmid that expressed only GFP that was not fused
to an activated caspase protein. Taken together, these data
suggest that activation is directly related to caspase
expression and apoptosis and is not a bystander
phenomenon.
Discussion
Many viruses, including HIV-1, have evolved functions




















































Fig. 8 Infectious virion production after induction of replication by apoptosis. The infectivity of virions produced via apoptosis-mediated HIV-1
activation was determined using luciferase assay by exposing 1G5 cells to supernatants from cells treated with cytotoxic agents. Equal amounts
(200 ng) of virus-containing supernatants, as determined by p24 assays were added to the 1G5 cells (with or without AZT, 5 μM) and luciferase
activity determined. Infectious virus was produced following induction of replication with both conventional induction and apoptosis induction.
For mock infections, 1G5 cells were incubated with culture supernatant of Jurkat cells treated with TNF-α. Values represented as
mean ± SD (n = 3)
Khan et al. Retrovirology  (2015) 12:42 Page 11 of 19(reviewed in [69, 70]). We, and others, recently showed
that herpesviruses can apparently sense host cell apop-
tosis and respond by initiating an alternative, rapid or
disordered program of viral replication that does not use
the same regulatory proteins used by the conventional
replication pathway, and produces virions of decreased
infectivity [52–55]. Our current study suggests that
HIV-1 can also sense host cell apoptosis and initiate rep-
lication in response. The ability to sense when the host
cell is about to undergo apoptosis and respond by initi-
ating viral replication would seem to offer viruses cap-
able of long term latency a substantial evolutionary
advantage: otherwise any viruses living latently in host
cells that underwent apoptosis would not reproduce.
The existence of conceptually similar abilities to sense
and respond to host cell apoptosis by two very different
viruses capable of long term latency may suggest that
any virus capable of long term latency would have likely
evolved some kind of analogous alternative apoptosis-
triggered replication pathway.
How activated caspases trigger replication of latent
virus – HIV-1 or herpesviruses – is not completely under-
stood, but one plausible hypothesis would be that caspase-
mediated cleavage of a viral or host factor converts an inert
protein into a potent transactivator. For herpesviruses,
there is evidence that some viral proteins are the targets
of caspase activity. For example ICP-22, a protein of HSV-1 involved in maintaining latency has been shown to be
cleaved by capase-3 [71]. While the sensing mechanisms
for both herpesviruses and HIV-1 involve activated cas-
pases, the downstream details of the mechanisms are
likely to be very different given the great differences in
the viruses, with host cell proteins much more likely to
be involved in the HIV-1 sensing mechanism due to its
much smaller genome size and complement of encoded
proteins.
There has been ongoing interest in the relationships
between apoptosis and HIV-1 replication and pathogen-
esis beyond the important studies that describe how
HIV-1 inhibits host cell apoptosis during viral replica-
tion. Treatment of latently infected host cells with Z-
VAD-FMK enhances production of HIV-1 replication
when viral replication in those cells is initiated by treat-
ment with TNF-α, but no direct effect on the virus was
observed [65]; the increase in HIV-1 production likely
resulted from Z-VAD-FMK inhibiting host cell apoptosis
during the process of viral replication, protecting that
process, like the helpful effects of HIV-1’s own anti-
apoptotic activities. We also observed that Z-VAD-FMK
could enhance TNF-α’s capability to induce latent HIV-1
compared to TNF-α alone Fig. 10 (d and e). Studies of
the relationship between HIV-1 latency and host cell
apoptosis also have interesting clinical implications.
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Fig. 9 Apoptosis-triggered HIV-1 activation is caspase dependent. U1 cells were pre-treated with increasing concentrations (0-100 μM) of the
pan-caspase inhibitor, Z-VAD-FMK for 2 h. U1 cells were treated with pro-apoptotic agents; (a) etoposide, (b) doxorubicin and (c) vincristine to
induce apoptosis for 36 h. Cells were stained with Annexin V and 7-AAD and assayed for apoptosis (solid line) using flow cytometry. HIV-1
activation was assessed by quantification of unspliced viral RNA using qRT-PCR and represented as fold change compared cells treated with
DMSO-containing medium without cytotoxic agents (dashed line). Culture supernatants were assayed for virus released by determining amount
HIV p24-antigen (ng/ml) (dotted line) p24 ELISA. Treatment with all cytotoxic agents led to apoptosis-mediated activation of HIV-1 in U1 cells,
which was blocked in a dose-dependent manner by the caspase inhibitor, Z-VAD-FMK. (d and e) Cells were treated with PMA as a positive control
for HIV-1 activation through the conventional pathway. The data represented are the mean ± standard deviation (n = 3)
Khan et al. Retrovirology  (2015) 12:42 Page 12 of 19devising ways to specifically induce apoptosis in cells la-
tently infected with HIV-1 as a way of attacking and de-
pleting the reservoir of cells latently infected with HIV-
1, as a way of effecting a cure for HIV infection
(reviewed in [10, 72]). If such strategies are used, given
our findings, it may be helpful to consider that treating
patients with agents to induce apoptosis in an effort to
deplete the latent reservoir may lead to the activation of
HIV-1 replication and the production of large amounts
of virus.
The observations that HIV-1 can sense host cell apop-
tosis, notably when triggered by cytotoxic drugs used as
cancer chemotherapy and bone marrow transplant condi-
tioning agents, suggest some additional clinical implica-
tions of our findings. The most dramatic reductions in the
HIV-1 latent reservoir have been observed in patients
treated with highly cytotoxic chemotherapy and bone mar-
row conditioning regimens. The reservoir reduction inthese patients has conventionally been attributed to the de-
struction of the cells that constitute the long lived reservoir
of latently infected cells, perhaps with some additional con-
tribution of a graft vs. infected cell immune response in
the bone marrow transplant patients. Our data suggests
that activation of latent virus by host cell apoptotic signals
might also contribute to reservoir reduction, particularly
when the infection of new cells is blocked.
A detailed understanding of the pathways that mediate
HIV-1 apoptosis sensing and replication might lead to
the identification of new, targetable elements of those
pathways. Given the potent activation that we observed
in the latently infected cells, particularly those arrested
in G1, and the substantial reductions in the HIV reser-
voirs observed in patients treated with cytotoxic drugs,
targeting these points may be particularly effective at ac-
tivating HIV, even in cells in which HIV previously avail-
able activating agents were not effective. While trying to














































































































































































































































Fig. 10 Inhibition of caspase activity and apoptosis-triggered HIV-1 activation in ACH-2 cells. ACH-2 cells were pre-treated with increasing concentration
(0–200 μM) of pan-caspase inhibitor, ZVAD-FMK for 2 h prior induction of apoptosis by (a) etoposide, (b) doxorubicin and (c) vincristine. Cells were
harvested 36 h post treatment and stained with Annexin V and 7-AAD to assay for apoptosis (solid line) by flow cytometry. HIV-1 unspliced viral RNA was
quantified using qRT-PCR and HIV-1 activation was represented as fold change compared to control treatment (dashed line). ACH-2 cells
were treated with TNF-α to induce viral replication through the conventional pathway as positive control. Apoptosis-mediated release of
HIV-1 virions in culture supernatants was determined by ELISA for HIV-1 p24 antigen (dotted line). (d and e) The levels of apoptosis (white
bars), HIV-1 activation (black bars) and (e) virus production followed by TNF-α treatment was determined as in panel A–C. Cells were also
pretreated with Z-VAD-FMK (100 μM) for 2 h, followed by TNF-α treatment to determine whether caspase inhibition reduces HIV-1
activation triggered by conventional pathway. Results are pooled from three independent experiments ± SD
Khan et al. Retrovirology  (2015) 12:42 Page 13 of 19attack and deplete the reservoir of latently infected cells
with cytotoxic agents is clearly impractical, studies of
the pathways that mediate apoptosis-initiated HIV repli-
cation might lead to the identification of new activating




HIV-1 latently infected model cell lines U1 [73], derived
from the U937 promonocytic cell line and ACH-2 [74]
derived from the A3.01 T lymphocytoid cell line were
obtained from NIH AIDS Research and Reference Re-
agents Program. The cells were maintained in RPMI
1640 (Invitrogen) medium supplemented by 10 % fetal
calf bovine serum (FBS, Hyclone), 1 % L-glutamine(Sigma Aldrich), penicillin (100 IU/ml) and streptomycin
(100 μg/ml) (Sigma Aldrich).
Induction and determination of apoptosis
Cytotoxic drugs etoposide (VP-16), fludarabine
phosphate, doxorubicin and vincristine (all from Sigma-
Aldrich), dissolved in dimethyl sulfoxide (DMSO, Sigma-
Aldrich) were used to treat cells. To expose the cells to
the cytotoxic drugs, the cells were collected, washed
with serum-free medium, resuspended in complete
medium with final cell concentration of 0.25 × 106 cells
per ml. Cells were exposed to the drugs at final concen-
trations as mentioned in figure legends. We used phor-
bol myristyl acetate (PMA) (25 ng/ml; Sigma Aldrich)
and tumor necrosis factor-α (TNF-α) (20 ng/ml; Invitro-






























































































































































Fig. 11 Effects of selective caspase-3 and caspase-8 inhibition on apoptosis induced by cytotoxic agents and associated HIV-1 replication. U1 cells
were pre-incubated with in medium with added DMSO alone or with 100 μM of caspase-3 inhibitor (C3i, ZDEVD-FMK), caspase-8 inhibitor (C8i,
ZIETD-FMK) and caspase-9 inhibitor (C9i, ZLEHD-FMK) alone or in combination for 2 h. After incubation with the caspase inhibitors, the U1 cells
were treated with (a) etoposide or (b) doxorubicin to induce apoptosis. Apoptosis was assessed after 36 h by Annexin-V-FITC staining and flow
cytometry. Total RNA was extracted from each sample and HIV-1 unspliced RNA was quantitated by real-time PCR TaqMan assay (Methods and
Materials). White bar represents percent apoptosis and black bar represents fold increase in HIV-1 unspliced RNA compared to DMSO treated cells.
Mean values and SD of three independent experiments are shown







































































































Fig. 12 Overexpression of caspase-3 and caspase-8, induction of apoptosis in HIV-1 latently infected cells and activation of HIV-1 replication. (a) U1 cells
were transfected with pmaxGFP or pCasp3GFP or pCasp8GFP construct were subjected to Annexin V staining followed by flow cytometry, gating on GFP-
positive cells, at 36 h post transfection (grey bars). HIV-1 activation was assessed by quantification of unspliced viral RNA using qRT-PCR and represented as
fold change compared to DMSO treated cells (black bars). The data are shown as mean ± standard deviation (n = 3). (b) Whole cell lysates obtained from
transfected cells were subjected to immunoblotting using anti-GFP, anti-HIV p24 and anti-GAPDH antibodies. Anti-GFP used in this experiment is raised
against GFP from Aequorea victoria while GFP expressed from pmaxGFP® (Lonza) is from Pontellina plumata, therefore antibody could not recognize GFP in
pmaxGFP® transfected cell lysate. (c) Transfected U1 cells were fixed and permeabilized using BDcCyto Fix/Perm solution and stained with HIV-1 p24 anti-
body (PE conjugated), samples were analyzed using flow cytometry. Upper panel represents untransfected and GFP alone transfected cells while lower
panel shows data of caspase-GFP transfected cells
Khan et al. Retrovirology  (2015) 12:42 Page 15 of 19post treatment, cultures were divided in two parts, one
for RNA extraction and p24 assay in the supernatant
and another for Annexin V staining to measure
apoptosis.
Cells were collected in 1.5 ml microcentrifuge tubes
by centrifugation at 1200 rpm for 5 min. To assay for
apoptosis, the cells were washed with cold 1X phosphate
buffered saline (PBS) and resuspended in 100 μl of 1X
binding buffer (BD Biosciences). We added 5 μl of
Annexin V-FITC (BD Biosciences) to the samples and
incubated the cells for 20 min in the dark at room
temperature before mixing with 400 μl of 1X PBS sup-
plemented with 7-AAD (7-Aminoactinomycin D)
(10 μg/ml). The cells were analyzed using a FACSCanto-
II flow cytometer (BD Biosciences). Untreated cells were
used to establish forward- and side- scatter gates. Data
was analyzed with FACSDiva software (BD Biosciences).
Apoptosis inhibition
The general caspase inhibitor, Z-VAD-FMK (Enzo Life
Sciences) and specific caspase inhibitors, Z-DEVD-FMK(caspase-3 inhibitor), Z-IETD-FMK (caspase-8 inhibitor)
and Z-LEHD-FMK (caspase-9 inhibitor) (all from BD
Bioscience) were reconstituted in DMSO (Sigma Al-
drich) to a stock concentration of 10 mM. Cells were
collected, washed with PBS, resuspended in culture
medium at final concentration of 0.25 × 106 cells per ml.
For apoptosis inhibition, cells were pre-treated with spe-
cific inhibitors of caspases (0-200 μM) for 2 h before in-
ducing apoptosis by cytotoxic drugs. PMA (25 ng/ml) or
TNF-α (20 ng/ml) were used as positive control HIV-1
activators. The treated cells were incubated for 36 h in
5 % CO2 and 37 °C in humidified atmosphere. After
36 h cultures were divided and collected in two parts,
one for RNA extraction and another for Annexin-V
staining.
Assays for HIV-1 RNA
RNA was extracted from the cell pellet using the RNeasy
Mini Kit (Qiagen) according to the manufacturer’s
protocol. RNA was quantified using a NanoDrop HD-
1000 Spectrophotometer (Thermo). Only samples with
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500 ng of total RNA per sample for reverse transcription
reactions using iScriptTM Reverse Transcription Super-
mix for qRT-PCR (Bio-Rad) according to manufacturer’s
protocol. Briefly, the RNA was mixed with 4 μl of 5 X
iScript RT Supermix and total reaction volume was
made-up to 20 μl by adding RNase-free water (Qiagen).
For negative control or no reverse transcriptase control
(NRTC) we used reaction mixture made by mixing
RNA, water and 4 μl of 5 X iScript no-RT supermix. The
reactions were incubated for 5 min at 25 °C for primer
annealing, 60 min at 42 °C for reverse transcription and
then at 85 °C for 5 min for enzyme inactivation. The
cDNA reactions were diluted 10 fold and 2 μl of diluted
cDNA was used in real time PCR reactions. For the
qPCR reactions we used TaqMan master mix system
(Applied Biosystems) and TaqMan probes specific for
HIV-1 late RNA (unspliced RNA) (IDT) and human
GAPDH (Applied Biosystems). The sequences of
primer sets used to amplify HIV-1 unspliced RNA
were 5′-ATAATCCACCTATCCCAGTAGGA GAAAT-3′
(SK38) 5′-TTTGGTCCTGTGCTTATGTCCAGAATGC
(SK39) [75]. A FAM-TAMRA-labeled probe 5′-ATCCTG
GGATTCAATAAAATAGTAGAGATGTATAGCCCTAC-
3′ was used for quantitation of late viral RNA species [75].
The thermal cycling conditions were 50 °C for 2 min and
an initial denaturation at 95 °C for 15 s followed by
40 cycles at 95 °C for 15 s and 60 °C for 60 s using the
Applied Biosystems 7500 Fast Real Time PCR detection
system. All reactions were performed in 20 μl final
volume, with human GAPDH was used as endogenous
control and NRTC as negative control. The amount of
PCR product was determined by the comparative 2-ΔΔCt
method [76], with each sample normalized to human
GAPDH and expressed as a fold-increase versus untreated
controls.
HIV-1 p24 protein detection by flow cytometry
To measure HIV-1 p24 protein expression, cells were
fixed and permeabilized with BD Cyto Fix/Perm kit (BD
Biosciences), washed with PBS containing 1 % FCS, and
stained with anti-HIV-1 p24 phycoerythrin mAb KC57
(Beckman Coulter) at 1:500 dilution. Isotype-matched
mAbs were used as negative controls. Samples were ana-
lysed with (BD Biosciences) and FloJo software.
Induction of G1-phase arrest and cell cycle analysis by
flow cytometry
Simvastatin, a potent G1-phase blocker was purchased
from Sigma and dissolved in DMSO. Cells in a density
of 0.25 × 106 /ml were serum starved for 12 h and then
treated with Simvastatin (5 μM) for another 18 h. Cells
were collected and fixed by resuspending them in 0.5 ml
of 100 % ethanol (ice-chilled) for 30 min on ice and thencentrifuged at 1500 rpm for 10 min and washed in ice-
cold PBS + 1 % serum. The cell pellets were resuspended
in 0.5 ml PBS + 1 % serum containing 50 μg/ml propi-
dium iodide (BD Biosciences) and 100 μg/ml RNase
(Invitrogen), incubated at 37 °C for 30 min, and then
analyzed using a FACSCalibur flow cytometer (Becton
Dickinson)
Determination of HIV-1 virion infectivity
The 1G5 cell line, a Jurkat derivative containing a stably
integrated HIV-LTR-luciferase construct [62], was ob-
tained from NIH AIDS Research and Reference Reagents
Program and maintained in 10 % FBS (Hyclone), 1 % L-
glutamine (Sigma Aldrich), penicillin (100 IU/ml) and
streptomycin (100 μg/ml) (Sigma Aldrich). For the in-
fectivity assay, cells were seeded at 0.2 × 106 cells per
well in 0.5 ml of RPMI 1640 supplemented with 10 %
fetal bovine serum and Polybrene (4 μg/ml, Sigma). Cells
were left untreated or treated with 3′-Azido-3′-deox-
ythymidine, 5 μM (AZT, Sigma Aldrich) for 2 h prior to
infection with HIV-1 virions (200 ng) normalized ac-
cording to p24 amounts present in cell-free culture su-
pernatants of drug-treated ACH-2 cells. 1G5 cells were
incubated with virions in 0.5 ml of complete medium
supplemented for 4 h with continuous rocking at 37 °C
in the presence of Polybrene (4 μg/ml) (Sigma Aldrich)
and AZT (5 μM). The cells were washed 2 times with
serum-free media to remove unbound HIV-1 and re-
suspended in 2 ml fresh complete media containing
AZT (5 μM) and incubated for an additional 44 h at 37 °C
in humidified CO2-incubator. Post 44 h incubation, cells
were harvested and lysed using 200 μl of 1X cell culture
lysis reagent (CCLR, Promega). Luciferase assays were
performed on clarified lysate using BrightGlo Luciferase
Assay System (Promega) according to manufacturer’s
instructions.
Treatment of cells supporting active viral replication with
cytotoxic agents
Jurkat T-cells were obtained from NIH AIDS Research and
Reference Reagents Program and maintained in 10 % FBS
(Hyclone), 1 % L-glutamine (Sigma Aldrich), penicillin
(100 IU/ml) and streptomycin (100 μg/ml) (Sigma Aldrich).
For infection, cells were washed, seeded at 0.25 × 106 cells
per well in 0.5 ml of RPMI 1640 supplemented with 10 %
fetal bovine serum and Polybrene (4 μg/ml, Sigma) and in-
fected with HIV-1 virions present in cell-free culture super-
natants of TNF-α treated ACH-2 cells. Four hours post
infection cells were washed 2 times with RPMI to remove
the unbound virus and resuspended in 2 ml of fresh
complete medium. Apoptosis was induced by treating
the infected cells with etoposide (0.5 μM), doxorubicin
(0.5 μM), vincristine (1 nM) and fludarabine phosphate
(1 μM). Induction of apoptosis in these cells was
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was determined by qRT-PCR, as described above.
Transfection of cells with plasmids expressing caspase-
3—GFP and caspase-8-GFP fusion proteins
U1 cells were transfected with plasmids, pcasp3-Wt-GFP
(simplified to pCasp3GFP in the figures and text) a gen-
erous gift from Shinji Kamada, Biosignal Research Cen-
ter, Kobe University [67] and pEGFP-N1-caspase 8
(simplified to pCasp8GFP in the figures and text) a kind
gift from Eyal Gottlieb, The Beatson Institute for Cancer
Research, Glasgow, UK [68]. pmaxGFP® (Lonza) was
used for GFP-only control and pUC19 was used as a
negative control (Mock). Cells were seeded in 12-well
plates, and 2 h prior to transfection, the medium was re-
placed by RPMI 1640 medium without FBS and antibi-
otics. Lipofectamine 3000 (Life Technologies) was mixed
with 100 μl Opti-MEM I medium (Life Technologies) at
a 1:50 dilution and incubated for 10 min at RT. This
mixture was then complexed with 1 μg of plasmids and
2 μl of reagent P diluted in Opti-MEM and incubated at
RT for 25 min. The complex was added to the cells, and
the plates were gently rocked at 37 °C for 5 h. After 5 h,
medium was replaced with RPMI with 10 % FBS and
cells were incubated for 36 h. Cells were also treated
with PMA (25 ng/ml) as a positive control for HIV-1 ac-
tivation through the conventional pathway and etoposide
(10 μM) as a positive control for apoptosis induced by a
cytotoxic agent. After incubation, cells were harvested
and one aliquot was evaluated for Annexin-V-APC
staining, another aliquot was used for RNA isolation, as
described above, and a third aliquot was used for protein
isolation. For the protein isolation, the cell pellet was
lysed in TN-lysis buffer (20 mM Tris-Cl, 150 mM NaCl,
1 mM EDTA, 0.5 mM PMSF, 0.5 % NP-40 and 1X prote-
ase inhibitor) by incubating for 45 min on ice with inter-
mittent shaking. The protein present in the clarified
lysate was estimated using Bradford reagent (BioRad) ac-
cording to manufacturer’s instruction and 40 μg of pro-
tein in the lysate was used for immuno-blotting.
Monoclonal antibodies against GFP (Cell Signaling) and
GAPDH (HRP-labeled) (Abcam) were used at 1:2000 di-
lution. HIV-1 p24 was detected by using 1:100 diluted
supernatant fluid from the anti-HIV p24 hybridoma
183-H12-5C [77], obtained from the NIH AIDS Re-
search and Reference Reagent Program. Peroxidase-
conjugated anti-mouse antibody (Santa Cruz) was used
as secondary antibody to detect GFP and HIV-1 p24
proteins by chemiluminiscent immunoblotting detection
reagent (Amersham Biosciences).
HIV-1 p24 Capture ELISA
HIV-1 p24 antigen was quantified in drug-treated cell
culture supernatant by performing a p24 antigen enzymelinked immunosorbent assay (ELISA) using commer-
cially available ELISA kit (p24 HIV antigen ELISA kit,
Perkin Elmer) according to manufacturer’s protocol.
Statistics
Values represent the mean ± SD of at least three inde-
pendent experiments. Correlation between apoptosis
and HIV-1 activation was calculated by performing the
Spearman rank correlation test using SigmaPlot 11.0.
Data curve fitting (Gompertz) and non-linear regression
statistical analyses were accomplished using SigmaPlot
11.0 software.
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